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Abstract 
 
The recent demonstration that nanoparticles associated with various biological 
molecules and pharmacological agents can be administered systemically to 
humans, without toxicity from the particles, has opened a new era in the targeting 
of such particles to specific tissues in the body for the imaging and therapy of 
disease.  The majority of particles used for this purpose contain iron and are 
detected in the body by magnetic resonance imaging.  We believe a 
superconducting quantum interference device (SQUID) could provide  
quantitative and spatial information relevant to localization of superparamagnetic 
nanoparticles directed to a specific cell target in vivo.  We envision a  scanning 
system consisting of a DC induction field, a transport device, and an array of  
planar first order gradiometer coils coupled to DC SQUID amplifiers. We 
performed a set of computer simulations using experimentally determined values 
for concentrations of paramagnetic particles achievable in specific tissues of the 
mouse  in vivo and concentrations of particles linked to monoclonal antibodies 
specific to antigens of two human cancer cell lines in vitro. An instrument to 
target distance of 10 centimeters was selected so that for an average adult 
scanning both the anterior and posterior surfaces could provide coverage of most 
of the body. The simulations demonstrate the feasibility of SQUID magnetometry 
for monitoring achievable concentrations of superparamagnetic particles in vivo 
and raise the possibility of using this approach to detect and localize collections of 
abnormal cells targeted by such particles. 
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Introduction 
 
 
Diagnosis of cancers at an early stage of development allowing complete 
surgical removal remains the most effective means of curing these diseases 
despite intensive efforts for half a century to develop curative pharmacologic 
regimens.   Technological advances in imaging of abnormal structural features in 
organs has led to more effective methods for population screening for cancers 
but the successes are vastly outnumbered by the failures.  For example, the 
overall cure rate for breast cancer in the United States is about 85% because 
there are effective if imperfect methods for early detection e.g. mammography 
and physical examination.  However, for a tumor such as ovarian cancer, which 
produces few symptoms until it has spread regionally and for which there is no 
satisfactory method for population screening, the overall cure rate is about 35%.  
Detected at an early stage, usually by chance, ovarian cancer is almost 100 % 
curable. 
 
Thus, much cancer research has concentrated on developing better methods for 
detecting the presence of the disease at an early stage with a low cost non-
invasive technique suitable for population screening1. The most widely used 
methods for cancer imaging include plain x-ray with or without contrast medium, 
x-ray computed tomography (CT), magnetic resonance imaging (MRI), 
ultrasound, and positron emission tomography (PET). The most precise imaging 
techniques, MRI, PET, and CT are expensive and prohibitively so for large scale 
screening for cancer.  
 
Over the past decade, there have been many attempts to develop non-toxic 
reagents that target abnormal collections of cells and which can be detected by a 
non-invasive procedure.  One of the most promising approaches is the use of 
superparamagnetic nanoparticles (spnps) that are either actively concentrated 
into tissue such as lymph nodes, often the first site of cancer spread, or which 
are directed selectively to specific cell types by targeting molecules bound to the 
surface of the particles.    
 
 
Superparamagnetic nanoparticles, consisting usually of iron oxide cores 
surrounded by dextran, are remarkably non-toxic in vivo in animals and humans.  
Thus, spnps linked to monoclonal antibodies with specificity to unique or 
overexpressed surface antigens have been used extensively to purify bone 
marrow stem cells constituting 0.1% or less of the total cell population, from 
unprocessed samples of human bone marrow. The antibodies cling to stem cell 
allowing their isolation from the mass of cellular material by magnetic column 
chromatography.  The particles neither impair the ability of these stem cells to 
reconstitute the marrow of a leukemia patient nor do the particles appear to have 
any other toxic effects in humans.   
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Linking peptide sequences of the Tat protein of human immunodeficiency virus-
type 1 (HIV-1) particles can enhance the uptake of spnps into specific cell types.  
Using this approach, Lewin et al2 showed concentrations of 10 to 30 pg of 
superparamagnetic iron (0.5-2x107 nanoparticles/cell) could be incorporated into 
several types of human and mouse cells.  The particles did not affect cell viability 
and human bone marrow progenitor cells (CD34+ ) homed to the bone marrow in 
immunodeficient mice.  Individual cells loaded with spnps could be detected as 
signal voids in MRI images and the presence of spnps in specific organs eg, 
liver, were readily detected in vivo by a reduction in MRI signal intensity, in the 
environment of the particles. 
 
A striking demonstration of the safety and potential value of spnps in detection of 
prostate cancer metastatic to pelvic lymph nodes was reported recently by 
Harisinghani et al3 .  They administered spnps at a dose of 2.6 mg per kilogram 
of body weight to eighty patients with various clinical stages of prostate cancer.  
The particles concentrate in lymph nodes as one of a few preferential sites of 
tissue localization.  By performing MRI before and after particle administration, 
90.5 % of nodes found to have metastatic cancer  (documented histologically 
after surgical resection or biopsy) after spnps compared to only 35.4 percent 
detection by standard MRI (before spnps).   The basis for enhanced detection 
was distortion of the plain MRI image by the non-uniform suppression of the 
intensity of the T2 signal by spnps irregularly distributed in lymph nodes infiltrated 
by cancer cells. 
 
A more direct method to capitalize on the magnetic susceptibility of spnps for 
cancer therapy is in development.  Iron oxide particles bound to cancer 
chemotherapeutic agents are injected intraaterially and drawn through the walls 
of capillaries into the site of a cancer by an external magnet placed over the 
target site4. A clinical Phase I/II trial was recently completed in which the anti-
cancer drug doxorubicin absorbed onto microparticles was magnetically 
concentrated in the liver of patients with unresectable hepatocellular cancer.  
Concentrations of the drug at the target were not measured in patients but 
localization of the drug in the liver, caused by the by the magnet field, was 
assumed because of little doxorubicin in the systemic circulation. Evaluation of 
the therapeutic benefit of this approach has been approved for evaluation in a 
multinational clinical study (see web site for FeRx, Inc.:www.FeRx.com). 
 
Spnps offer many possibilities for specific cellular, disease and organ targeting 
for imaging and, potentially to achieve higher concentrations of molecules at sites 
of disease than are obtainable following systemic administration.  We believe the 
low toxicity of spnps in vivo in humans and the ability to target specific tissues, 
including cancers in vivo, make them their inducible magnetic fields attractive as 
a new modality for cancer screening.  The challenge is to create a detector 
sufficiently sensitive to rapidly acquire data on foci of increased magnetic signal 
in spatially defined volumes, which reveal the presence, and location of disease.  
 
 4
The objective of this study was to determine the physical parameters involved in 
detecting and localizing the magnetic field created by superparamagnetic 
particles localized on the tumor through phagocytosis or attached to tumor 
antigen-specific monoclonal antibodies targeted to occult human cancers  Over 
the last two decades dextran coated magnetic nanoparticles have found a variety 
of applications in the biological and medical sciences. Molday and Mackenzie5 
first describe the use of dextran-coated particles with a 15 nm iron oxide core 
coupled to antibodies and other ligand for cell separation in the laboratory. More 
recently a variety of smaller particles MIONS (Monocrystalline Iron Oxide 
Nanocolloid) 6, PION (Polycrystalline Iron Oxide Nanocolloid)7, LCDIO (Long 
Circulating Dextran-coated Iron Oxide)8 and USPIO  (Ultra Small 
Superparamagnetic Iron Oxide)9 have found application as contrast agents in 
MRI studies. These particles have been introduced in vivo and are found to be 
non-toxic. Maximum localization on a specifically targeted region (tumors, liver, 
lungs, lymph nodes) occur approximately 24 hours after injection and typically 
the majority of nanoparticles have passed out of the body within a week.  
 
There are approximately 109 cells in one gram of tissue.  If these cells formed a 
sphere, there would be about 106   cells comprising  the surface.  The recent 
demonstration by Lewin et al2  that , in vitro , biologic transporter molecules such 
as certain peptide sequences of HIV-1 attached to spnps can  achieve 
intracellular concentrations of iron of 10 to 30 pg of iron per cell or 10 to 30 ug 
per 106 cells, an amount for paramagnetic iron which should be detectable by 
induction of a local magnetic signal arising from the tumor volume.  Such 
concentrations have not yet been achieved in vivo but as methods of targeting 
cancer cells in vivo improve, achieving such concentrations of spnps in early 
stage cancer seems within the realm of possibility.  Even current methods of 
targeting result in concentrations of spnps in experimental tumors that we believe 
should be detectable by virtue of their magnetic susceptibility.  Thus Moore et al 8    
achieved concentrations between 11.9ng and 118ng of iron per million tumor 
cells growing as a mass in a rodent model after systemic injection of LCDIO.  We 
have modeled the ability of ultrasensitve SQUIDS to detect the magnetic fields 
that would be generated by these concentrations of iron.  
 
Ultra-sensitive SQUID (Superconducting Quantum Interference Device) 
amplifiers have been used for imaging the magnetic fields produced by electrical 
activities in the brain and heart. Naturally occurring biomagnetic signals in the 
body are very small it was not until the advent of SQUID technology that practical 
measurements of these signals have been attainable. Since the advent of 
SQUID technology much effort has gone into imaging and mapping the 
biomagnetic signals produced by electromagnetic signals in the brain and heart. 
SQUID helmets with large numbers of array elements10 (>100) have been 
produced to measure and map brain signals. Magnetocardiography (MCG)11 and 
Magneto-Encephalography (MEG)10 signals are time varying and produce 
changes in the magnetic flux outside the body. Since the inherent sensitivity  
(noise limit) is about 2 x 10-14T / Hz 12, operational bandwidths, we are 
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considering (.1-40 Hz), allow for sensitivities as low as approximately 1.5x10-13 
Tesla. System design and the ambient fields in the vicinity of the probe 
determine noise levels. Using gradiometer configuration pick-up coils signal 
levels on the order of 2 x 10-15T /cm are readily achievable with good system 
design13 in an unscreened relatively low noise environment. A diagram, which 
summarizes the sensitivities of some of the more common magnetometry 
techniques as a function of frequency, is Figure12.1 in Bioelectromagnetism14.  
 
SQUID scanner systems have been developed for use in Non-Destructive 
Evaluation15 (NDE) of materials. Limitations in the cost effectiveness and 
penetration depths have hindered the techniques commercial introduction and 
most SQUID NDE evaluation still takes place in university laboratories. SQUID 
scanners using an ac field16 have been used to determine the magnetic 
susceptibility of human organs in the body. While this type of system could 
potentially be used for the application we are describing, the ac field introduces a 
range of issues (electronic stability, balancing, eddy current noise etc.) that are 
for the most part avoided with our design. R. Ilmoniemi et al.12 developed a 
SQUID scanner with many of the attributes of  the system we are proposing. The 
main difference being that they were looking for a ferromagnetic inclusion 
(acupuncture needle) and hence their system has no inducing magnetic field. 
Other similar systems, used to measure iron stores in the liver have been 
described in the literature17 
 
 
We  investigate the limits of SQUID detection and localization on spnps at 
concentrations and at distances required for use of this technology as a rapid low 
cost method for screening for many types of cancers.  
 
Simulations 
A system for measuring the signature of a localized superparamagnetic particles 
within the body must have the following properties: 
1) An induction field. 
2) Method for inducing a magnetization induced flux change (ac field or 
motion). 
3) Method for measuring a magnetization flux change. 
4) Extreme stability  
5) Extreme sensitivity 
 
While the physical parameters to be measured are necessarily design 
dependent, we have chosen to simulate the system described below as it 
appears to be a straight forward and solves some of the problems inherent in the 
design of this type of measurement. 
 
The initial simulations were performed to identify theoretical limitations and 
determine the physical parameters under which a SQUID coupled sensing 
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device could obtain a signal from a superparamagnetic inclusion located in the 
body.  To do this we developed a brute force three-dimensional simulation of the 
body, superparamagnetic inclusion, applied magnetic field, and sensing coils. By 
necessity a scanner design must be chosen and a particular protocol simulated. 
We have chosen a scanner, which incorporates a DC superconducting induction 
field (low noise and highly stable) and uses motion of the patient to produce a 
flux change in the pick up coils. This design is simple, cost effective and flexible.  
 
The magnetic field was modeled as a racetrack geometry extending across the 
width of the body (Figure 1). Neglecting end effects (extending the magnet well 
past the width of the body), the magnetic field could then be modeled as a 
contribution from two wires separated by 14cm, each wire located 7cm on 
opposite sides of the scan point. To minimize ambient noise and the background 
signal, the pickup coils were modeled in a planar first-order gradiometer 
configuration18 with each of the counter wound pickup coils having an area of 
1cm2 and each coil located along the length-axis with the center of the coils 
displaced 2.5 cm on either side of the scan point, Figure 1. The magnetic field 
signal due to the inclusion and/or a background cube is calculated at a point at 
the center of each coil.  
 
The phantom torso (body) in our simulations was modeled as an ellipsoid filled 
with water. This approximation was used to determine the maximum absolute 
contribution of a large slowly varying diamagnetic background (of approximate 
torso dimensions) with rapidly varying edges. There are clearly limitations on the 
information that can be obtained from this simple model but the model is useful 
for determining some of the limitations of the technique. 
 
A three dimensional rectangle was formed with dimensions of length 120cm, 
width 20cm and thickness 20cm, Figure 2. The dimensions of the rectangle were 
then divided into mm3 cubes and the magnetization from each cube contributes 
to the measured signal. The torso was modeled in the rectangular box as an 
elongated ellipsoid with the same maximum dimensions as the rectangle. During 
the summing of the magnetic field contributions of the magnetization, cubes 
located outside the ellipsoid produced no contribution to the field at the sensing 
coils. Cubes located inside the ellipsoid had a diamagnetic response to the 
applied field and produce a corresponding contribution to the field at the SQUID 
sensing coil. The Molar Diamagnetic susceptibility of water is –13x10-6 
(emu/mole). The tumor was modeled as a paramagnetic inclusion and could be 
located at various positions within the ellipsoid. The tumor with magnetic particles 
was represented as the contribution from 1mm square cube located within a 1cm 
diameter sphere. These “tumor” cubes had both a diamagnetic contribution 
(body) and a paramagnetic contribution due to the magnetic nanoparticles. 
Experimentally determined values for the paramagnetic contributions will be 
described in the next section. 
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The magnetic field located at a distance r from a solenoid wire has a magnitude 
equal to B(r)=C/r where C is a constant determined by the magnetic field at 1 cm. 
This field was taken to be 3500 G, producing a total magnetic field of 1kG at the 
central scan point. The field is a vector quantity radiating tangentially from a 
circle or radius r centered on the wire. The field due to the second wire circulates 
in the opposite direction giving a significant cancellation of the x components 
near the vertical line passing through the scan point. The y-components of the 
magnetic fields located near the same vertical line add, producing strong vertical 
polarization of the diamagnetic ellipsoid and the magnetically enhanced tumor. 
By knowing the direction of the magnetic field and magnetic susceptibility at any 
point in the matrix we can calculate the magnetization vector. Treating the 
magnetization of a mm3 cube as a magnetic dipole we can calculate the 
magnetic field produced by the sample magnetization at the position of the pick 
up coils.  
 
The scan covers the upper positive quadrant of the three dimensional rectangle 
and hence the upper quadrant of the ellipsoid. The rectangle and ellipsoid were 
shifted by 10cm from the X-Y plane to allow for a scan across the full width of the 
body.  In general the pickup coils were placed 1 cm from the top of the ellipsoid. 
A scan at any one scan point includes a scan volume of 140 mm along the 
length, 200mm along the width and 100 mm of thickness and the magnetic field 
is calculated at each of the two counterwound pickup coils for each of the ten 
scan elements. The 140 mm finite length of the scan volume has the effect of 
clipping the generated signal at distances greater then or equal to 7 cm from the 
tumor along the length axis. As the scanner is moved the length of the body 600 
of these scan volumes are included in the total scan. We estimate that the total 
11 SQUID simulation includes approximately 1x1011 calculations and takes 
approximately 9.5 hours on a 960MHz Pentium III PC. Even so the mm3 grain 
size appears as rapid jumps in the torso contribution as the mm3 grains are 
limited by the smooth ellipsoidal function and in the tumor contribution as the 
mm3 grains are limited by a smooth spherical function. 
 
Experimental Determination of Simulation Parameters 
Magnetic Nanoparticles 
Two types of targeted nanoparticle contributions to the paramagnetic moment of 
the tumors were considered.  The first targeted nanoparticle we will consider is 
used in MRI contrast imaging. The paramagnetic contribution was calculated 
using the parameters given in Shen et al.6, who studied the behavior of magnetic 
nanoparticles uptake by mouse brain tumors as a contrast agent for MRI. Tumor 
cell uptake of LCDIO, in a rodent model, was found to be between 11.9ng and 
118ng of iron per million cells8.  In this study the LCDIO data is being used to 
determine that the minimum signal and we therefore use a value of (12.5ng of 
iron)/(1 million tumor cells), at the bottom range of their reported results. Using 
the reasonable assumption that there are approximately 1x106 cells/mm3, we 
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estimate that a 1 cm3 tumor to contain 12.5µg of Fe. From the graph of the 
magnetization vs. field in Shen et al. we observed that the saturation 
magnetization occur for magnetic fields > 5 kG.  In the field range we will be 
working, < 2 kG, the magnetization vs. field is approximately a straight line and 
from this observation we took the magnetic susceptibility for fields less then 2kG 
to be 2.2x10-2 emu/gm (Fe).  Simulation results using these parameters are 
labeled LCDIO.   
The second set of parameters which we used to simulate maximal targeting of 
the cancer tumor were obtained from in vitro targeting to specific lines of cancer 
cells with monoclonal antibody attached magnetic nanoparticles.  These 
conjugates are produced commercially by Miltenyi  Inc. for use in cell separation. 
Due to the high number of potential binding sites on the cancer cells, we chose to 
use Miltenyi’s anti-cytokeratin monoclonal antibodies that were conjugated to 
magnetic nanoparticles.  Simulation results using these parameters are labeled 
MACS. 
 
LNCaP human prostate cancer cells and MCF-7 human breast cancer cells were 
grown at 37° C and 100% humidity in Dulbecco’s modified Eagle’s medium 
containing 10% fetal bovine serum. Both cell lines were routinely subpassaged to 
maintain them in log-growth phase. To label the LNCaP and MCF-7 cells with the 
magnetic anti-cytokeratin antibodies, the cells were harvested by quick 
trypsinization, and pelleted in a clinical centrifuge. Following a short wash with 
phosphate buffered saline solution, the cells were again pelleted and allowed to 
dry briefly. The antibodies were then bound to the LNCaP and MCF-7 cancer 
cells as per the manufacturer’s protocol. Following antibody binding, the cells 
were counted with a hemocytometer and aliquoted into microfuge tubes for 
SQUID analysis. 
 
To determine the physical parameters associated with using the MACS particles 
in the simulation we performed a series of experiments using a Quantum Design 
SQUID magnetometer.  Miltenyi literature describes their particles as 
polysaccharide coated iron oxide nanoparticles approximately 50 nm in diameter.  
To obtain an estimation of the mean size of the iron oxide component of the 
nanoparticles we have measured the field cooled and zero field cooled 
magnetization as a function of temperature (Figure 3a).  The blocking 
temperature of iron oxide nanoparticles is well-known as a function of 
temperature and from the observed blocking temperature we estimate that the 
iron oxide particles in the Miltenyi microbeads have a mean in diameter of 
approximately 6-10 nm. We do not expect that the distribution contains significant 
number of particles greater then 10 nm since this would produce of remanence at 
temperatures greater than the measured blocking temperature. To determine if 
the nanoparticles are truly superparamagnetic or if they have some remnant 
moment we measured in the in-phase and out-of-phase magnetic susceptibility of 
the particles, between 1 Hz and 1000 Hz, at 310 K (Figure 3b). it can easily be 
seen that these particles are paramagnetic.  There is a large approximately 
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constant component of the magnetic susceptibility and the out-of-phase 
component is very small over the whole frequency range in but does increase as 
a function of frequency.   
 
To determine the magnetization values to be used in the simulation we measured 
the magnetization as a function of magnetic field for the particles targeted to the 
LNCaP and MCF-7 cancer cells at 310 K (Figure 4).  One significant difference 
between the MACS particles and the LCDIO particles is that the MACS particles 
require a much lower magnetic field to obtain saturation magnetization. The data 
was fit to a Langevin function for a collection paramagnetic particles.  From these 
fits the magnetization/particle was determined and found to be consistent with 
what would be expected for 8-10 nm sized Fe3O4 nanoparticle.  The breast 
cancer cells were each determined to have picked up approximately 3.3 x 105 
MACS particles.  The prostate cancer cells had binding values approximately one 
of order of magnitude less then that obtained for the breast cancer cells.  We fit a 
9th order polynomial function to the magnetization (M) vs. magnetic field (H) 
curve and used the function M(H) in the simulations.  At each cube of tumor cell, 
in the simulation, we first determine the value and direction of the magnetic field.  
Then using the M(H) function we determine the magnetization vector for that 
cube.  
  
Based on the concentration of  LCDIO nanoparticles achievable in tumor cells in 
vivo in a rodent model, we determined what we consider to be the minimum 
values required for detection of a useful signal in a screening system.  The 
MACS data provide the maximum possible targeting of a specific monoclonal 
antibody to two types of cancer cell lines. The MACS data provide a more 
idealized situation but one which points to the possibilities inherent in this 
technique. 
 
 
Results 
We first determined the feasibility of detecting  the magnetic field generated by 
the maximum number of MACS expected to be localized in tumor with a volume 
of one cubic centimeter.  To address this question, we need to consider the limits 
of SQUID technology and the effects of ambient noise. Our initial approach is to 
model detection of different strengths of generated signal assuming zero external 
noise and then to address the realities of background signal. 
 
The absolute magnetic field generated by a 1 cm3 tumor at various distances 
from the SQUID scanner is shown is Figure 5.  In this range, the signals are 
above detection limits. For example, magnetocardiogram signals have been 
detected with SQUID scanners in the sub pico-Tesla range. The signal from the 
LCDIO particles at a depth of 11 cm is  in the pico-Tesla range.  The signal from 
the MACS particles attached to the human breast cancer, at this depth,  is  four 
orders of magnitude greater than those from the LCDIO particles.  
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Far field noise reductions of two to four orders of magnitude can be achieved 
with a well-balanced gradiometer configuration for the pick-up coils. Currently 
lithographic techniques used to pattern planar pickup coils can provide excellent 
balance. While the differential magnetic field detected by gradiometer 
configurations is smaller then the absolute magnetic field, this difference is more 
then compensated for by the reduction (cancellation) in ambient noise. Figure 6 
is the scan, for an 11 SQUID scanner, neglecting the signal from the body. The 
spatial distribution of the differential scan signal at the various pickup coils, 
generated from a signal a depth of 5cm from the central pickup coil, is plotted. As 
the scanner moves across the length of the scan rectangle, the pickup coil on the 
near side begins to pickup the signal. The signal reaches a maximum close to 
the point where the pickup coil is positioned vertically over the tumor. The signal 
then goes to zero when the scan point is directly over the tumor and becomes  
negative as the other counterwound coil passes over the tumor.  
 
We believe that the pickup coils must  to be able to sense at a minimum of 10 cm 
into the body. For a maximum body thickness of 20 cm (for a patient lying on a 
flat table), the anterior and posterior surfaces would be scanned to include the 
entire anatomy. Allowing for 1cm clearance between the pickup coils and the 
body surface, the minimum scanning distance is 11 cm. The raw signal for a 
tumor located 11 cm from the pickup coils is shown if Figure 7 and the  maximum 
differential signals (signal from the pickup coil) from the tumor as a function of the 
vertical distance of the tumor from the scan point of the detector (for both LCDIO 
and MACS targeted MCF-7 human breast cancer cells) are shown in Figure 8. 
 
The magnitude of the signal for the LCDIO particles exceeds the resolution of the 
technique in an unscreened environment. However, the signal to noise ratio is 
probably not adequate for realistic and reproducible detection with  an expected 
ambient noise of about  10-12 Tesla. The LCDIO particles represent a minimum 
signal that has  been achieved in vivo. The targeted MACS produce a signal four 
orders of magnitude greater then that produced by LCDIO particles and are well 
within the detection limits of a SQUID scanner.  The MACS particles represent a 
maximum signal for cell targeting and as such provide an upper bound for 
targeting a 1 cm3 tumor with this particular size and type of magnetic 
nanoparticle. 
 
We simulated the effects of the diamagnetic background of the body. A tumor 
located in an ellipsoid of the susceptibility of water and positioned 11 cm from the 
SQUID sensor is illustrated in Figure 9.  The LCDIO value  at 6 cm results in a 
signal approximately equal to the maximum signal of the diamagnetic 
background and can therefore be resolved. It should be noted that the 
background has a noise associated with it, which appears as ripples. These 
“ripples” are an artifact of the algorithm, as previously described, but provide an 
artificially implemented noise level at approximately 0.1 nano-Tesla. While 
signals in this sub pico-Tesla regime have been measured in scanners, it is likely 
that the addition of the superconducting solenoid with a DC magnetic field of 
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approximately 0.1 Tesla will significantly increase the noise level.  Unlike a 
Helholtz coil where the vast majority of noise is induced through the electronics, 
a superconducting solenoid in its persistent mode is very stable and introduces 
very little noise. We expect the main source of noise to be from vibrations of 
surrounding materials in this magnetic field.  We believe a scanner, operating in 
the described magnetic fields, can be constructed with an intrinsic noise level  of 
~0 .1 nano-Tesla. We selected this level of noise to begin to set limits on this 
technique. This artificial noise is more then an order of magnitude larger then the 
signal of an LCDIO tumor at 11 cm making detection impossible.  To resolve a 1 
cm3 tumor at 11 cm, at this noise level, requires approximately two orders of 
magnitude more signal strength. Such signals are likely to be achievable as in 
vivo targeting of spnps evolve. 
 
To consider background signal, we investigated the effects of a uniform 
background signal upon detection of a tumor located in a large organ.  Moore et 
al.8 considered this issue with regard to 9L gliosarcoma brain tumors labeled in 
vivo in a rodent model.. In this study, uptake by the brain tumor was 
approximately 0.11% of injected dose and  the surrounding normal brain tissue 
had about on tenth of the tumor concentration of LCDIO. The effect of this type of 
background signal was investigated in Figure 11. We modeled a   1.0 cm3  tumor 
located in an organ at 5 cm from the scanner. The organ was modeled as a 
rectangular box with thickness 2.5 cm on either side of the tumor, width 5cm on 
either side of the tumor and length 5 cm on either side of the tumor in the 
direction of the scan length.  The organ was given an Iron Oxide concentration of 
1% of the tumor concentration. The diamagnetic background of the body was 
included. The scan in Figure 11 shows that a 1% organ background produces a 
signal comparable to the signal due to the tumor. At 1% the signal due to the 
tumor is still resolvable. Simulations were also done with a 10% background 
tumor. In these simulations the background signal is orders of magnitude greater 
then the tumor signal. Subtraction of this background signal is problematic and 
sets limits on contributions due to surrounding tissue. On the other hand for 
intravenously administered targeted Iron Oxide particles conjugated with 
monoclonal antibodies it was found that tissue surrounding the tumor had 
“modest” uptake but no evidence of the presence of monoclonal antibodies. This 
suggests that well constructed magnetic label-target specific vector conjugate will 
provide the best system for maximizing tumor uptake while minimizing 
background.  
 
The  body scans in the plane of the scanner, the XY plane, show that localization 
of the signal is a function of the number of pickup coils comprising the scanner. 
There are several attributes of the signal that may be used to determine depth in 
the body.  One well-known attribute is that the peak of the differential signal 
changes in position as a function of depth (Figure 1a). Another  perhaps more 
useful way of determining depth is suggested by the form of the magnetization 
vs. the magnetic field curve in Figure 4.  The deeper the tumor in the body, i.e. 
from the greater the distance to the scanner, the smaller the magnetic field. 
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When  the tumor signal is in the XY plane, a series of shorter length scans can 
be performed with increasing magnetic field.  This type of field scan, using the 
signal obtained from MACS attached to MCF-7A cells,  is illustrated  in Figure 
11b. The data as a function of magnetic field can be fit reasonably well by a 
power law and the exponent of the power law changes significantly as a function 
of tumor depth..  Therefore, it is possible to expand the signal as a function of the 
power law's and determine the signal has a function of depth.  
 
 
Discussion 
 
In a practical embodiment of the proposed scanner, the magnetic field solenoid 
and scan elements would be located beneath the patient facing upward.  The 
patient would be moved over the scanner on a flat conveyor system without 
contact with scanner.  Thus,  the scanner is  isolated from vibrations associated 
with patient movement. The magnetic field solenoid and pickup coil loops must 
be rigidly connected to each other.  In magnetic fields of a few kG, vibration or 
motion of the pickup coils will produce noise levels greater than the sample 
signals.  
 
The SQUID sensor is located approximately 30 cm from the pickup coils in a Nb 
enclosure.  The magnetic field should not  affect the SQUID.  Before  a scan, the 
SQUIDs can be reset to lock the trapped flux due to the superconducting 
solenoid in the pickup coil loops. Variations of magnetic field are measured with 
respect to this constant amount of trap magnetic flux. At reasonable transport 
rates of 5 to 10 cm per second so that  a body scan would be completed in 20 to 
40 seconds.  This rapid scan rate allows multiple scans to be averaged, reducing  
the signal to noise ratio. SQUID drift would be measured  measured before  a 
scan and compensated for over the duration  of the scan. 
 
While SQUID magnetometers have intrinsically high sensitivity, their behavior is 
usually limited by the ambient noise of the environment.  In the measurement 
mode considering,  the SQUID effectively integrates its signal over a large 
frequency range.  Although, noise can occur over a large range of frequencies.  
High pass filtering (> 1 Hz), by shorting the SQUID terminals with copper wire, 
can  reduce the inherent low-frequency noise..  A low pass filter less then 104 Hz 
will  reduce noise from radio waves.  However, geomagnetic noise, general low-
frequency noise due to motion of cars, trucks, air-conditioning, human activity, 
etc., and line frequency noise associated higher harmonics, may require  
enclosing  the scanner and transport mechanism in a room with electromagnetic 
and mu metal shielding.  Specific filtering of the SQUID signal at the line 
frequency and higher harmonics may also be needed.. 
 
In terms of the physical parameters analyzed in this simple model, values of 
magnetization in realistic magnetic induction fields are measurable with SQUID 
technology. There are several variables that can be potentially modified to 
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enhance the signals generated using this technique. It is clear that the 4 nm 
LCDIO particles, and uptake rates reported from MRI studies, provide enough 
signal for a 1 cm3 tumor to be detected at 10 cm depth in the body.  Even so the 
signal to noise ratio will be poor.  Uptake of the LCDIO particles occurs through 
phagocytosis and as such they are not specifically targeted to the tumor cells.  
The LCDIO samples are also not specifically designed to maximize the signal in 
a SQUID scanner.  Data from the MACS targeted samples offers an example of 
what maybe possible.  The MACS data is four orders of magnitude greater then 
the LCDIO data and would provide sufficient signal to noise ratio for a 1 cm3 
tumor to be observed at distances greater then 12 cm from the scanner.  In the 
body one would not expect this type of the maximal targeting that we have 
presented from in vitro combination of cells and targeted nanoparticles.  One 
might expect targeting ratios of the few percent of possible antigen sites thereby 
dropping the signal by one to two orders of magnitude. One possible direction for 
enhancing signal is therefore to maximize nanoparticle to tumor binding. The 
main parameters available for enhancement of the signal are related to the 
characteristics of the nanoparticles.  Nanoparticles moments, above the blocking 
temperature, increase as a function of the radius of the nanoparticles19. It could 
be argued that this increase goes approximately as the radius cubed.  Increasing 
the size of the iron oxide nanoparticles from a radius of 5 nm to radius of 25 nm 
(the maximum size for single crystal iron oxide nanoparticles) would give a signal 
increase of approximately two orders of magnitude.  This increase in size would 
also significantly raise the blocking temperature and increase resonance.  There 
is a large amount of work being done to develop nanoparticles for a variety of 
applications. For this application ideal nanoparticles would have the following 
properties: 
1) A blocking temperature less then 310K,  
2) Maximized magnetic moment (as a function of size and constituents)   
3) Non-toxic 
4) Small enough to pass though the endothelio-reticular system. 
5) Coated to evade the bodies defenses 
 
 
We also analyzed a 1cm3 tumor at 5cm within a simulated organ of thickness, 
width and length, 5cmx10cmx10cm consisting of a diamagnetic water 
concentration and a 1% of tumor concentration superparamagnetic contribution. 
The organ contribution was as large as the tumor signal suggesting the need for 
efficient targeting. One other way to reduce contributions from an organ would be 
to measure and then model the organ uptake and subtract the signal from the 
scan.  Theoretically any tumor with signal greater than the minimum noise 
constraints could be identified. 
 
In conclusion, magnetic field signals from a 1 cm3 tumor loaded with in vivo 
determined values (LCDIO) of iron oxide nanoparticles produces significant 
enough signal to be measured with a DC SQUID scanner at depth of 11 cm.  
However when the expected level of noise for this particular type of scanner, is 
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taken into account, the signal is not resolvable. It must be pointed out, that these 
contrast agents were not designed for this type of magnetization measurement 
and hence it is likely that the signal could be greatly improved.  Nanoparticles 
targeted to cells in vitro (MACS) produce signals four orders of magnitude larger 
than those produced by LCDIO particles. At these signal levels tumors, at depths 
greater than 11 cm, can be detected by a SQUID scanner with signal to noise 
ratios greater then 100: 1.  We believe that highly efficient tumor targeting and 
maximization of nanoparticle magnetic moment will be achieved in the near 
future making SQUID magnetometry an important modality for cancer screening. 
 
 
The authors would like to thank Bob Fagley, Bob Kraus and Raymond Orbach for 
useful discussions.  
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Figures: 
 
 
Figure 1. Illustration of hypothetical SQUID scanner modeled in 
simulations. 
Scanner is composed of  ten planar first order gradiometrer pickup coils located 
to the interior of and on the same platform as a superconducting solenoid. The 
value of the magnetic field is the field generated at the midpoint of a set of coils 
of a pickup coil. This is also defined as the scan point. End effects of the solenoid 
are neglected.   
 
Figure 2:  Computer Simulated Body, Tumor and Scan Geometry 
The scan covers the upper positive quadrant of the three dimensional rectangle 
and hence the upper quadrant of the ellipsoid. The rectangle and ellipsoid were 
shifted by 10cm from the X-Y plane for mathematical simplicity (all positions in 
this quadrant are positive definite).  The pickup coils, located in the scanner are 
located 1 cm above the top of the rectangle.  The magnetic field is in a racetrack 
configuration centered around the scanner platform.  
 
Figure 3:  Magnetic Properties  of MACS particles. 
a) The zero field cooled and field cooled magnetization of 50 microliters of  
MACS solution measured in the magnetic field of 100 G. 
b)  b) The in-phase and out-of-phase components of the ac susceptibility as a 
function of frequency of 50 microliters of  MACS solution. 
 
Figure 4: Magnetization Vs Magnetic Field     
a) 106 cells MFC-7a MACS conjugated Human  Breast cancer cells,   
b) 106 cells LNCaP MACS conjugated Human  Prostate cancer cells.  
 
Figure 5: Absolute magnetic field (single coil) at the scanner due to 
enhanced magnetization as a function of perpendicular distance from the 
scanner.  Distance to scanner varies from 2cm to 11 cm. Edge effects of signal 
are due to a finite scan volume width and accentuated by the log scale. The 
magnetic field applied was  .1 T (1000 G) at the scan point.  
 
Figure 6:  Line scan of magnetic field differential vs. Scan Distance MACS 
conjugated to MCF-7 cells  
No background. Tumor is located at x=10 cm (100mm) y=6 cm (5 cm depth from 
pickup coils) and z=10cm (center of the ellipsoid). Scan produced by 11 SQUID 
scanner. 
 
Figure 7:   Signal From Tumor Located 11cm deathblow the SQUID Sensor 
Tumor is located at x=10 cm (100mm) . Scan produced by 11 SQUID scanner. 
Maximum differential signal is plotted as a function of the scan distance.  
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Figure 8:  Differential Magnetic Field Signal Maximum as a function of 
distance of 1 cm3 tumor from the scanner.  The magnetic induction field 
applied was  .1 T  (1000 G) at the scan point.  
 
Figure 9:  Differential magnetic field scan (output from first order pickup 
coil subtraction) as a function of scan distance.  
a) A 1cm3 LCDIO tumor located 100 mm from the y-axis and located at a 
distance of 5 cm from the central scan point and a depth of 4 cm below 
the surface of the diamagnetic ellipsoidal background.  
b) A 1cm3 MCF-7 MACS targeted constructed tumor located 100 mm from 
the y-axis and located at a distance of 11 cm from the central scan point 
and a depth of 10 cm below the surface of the diamagnetic ellipsoidal 
background.   
Simulated signal generated by 11 SQUID Scanners scanning the width of the 
ellipsoid. The magnetic induction field applied was  .1 T (1000 G) at the scan 
point.  
 
Figure 10:   Line Scan: Tumor at 10cm plus Virtual Organ Background  plus 
Diamagnetic Background 
For ellipsoidal background. Tumor is located at x=10 cm (100mm) y=1cm (10 cm 
from pickup coils) and z=10cm (center of the ellipsoid). Scan produced by 11 
SQUID scanner.  
 
Figure 11:  Depth Dependence of Scanner  Signals. 
a) The position of the peak in the in the Differential Magnetic Field signal 
from the tumor as a function of tumor depth.   
b) Amplitude of the maximum Differential magnetic field signal from the 
tumor as a function of magnetic field for tumor is located and varying 
depth. 
The magnetic induction field applied was  .1 T (1000 G) at the scan point. 
. 
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Figure 3:  Magnetic Properties  of MACS particles. 
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Figure 4: Magnetization Vs Magnetic Field     
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Figure 5: Absolute magnetic field (single coil) at the scanner due to 
enhanced magnetization as a function of perpendicular distance from the 
scanner 
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Figure 6:  Line scan of magnetic field differential vs. Scan Distance MACS 
conjugated to MCF-7 cells  
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Figure 7:   Signal From Tumor Located 11cm deathblow the SQUID Sensor 
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Figure 8:  Differential Magnetic Field Signal Maximum as a function of distance of 
1 cm3 tumor from the scanner.   
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Figure 9:  Differential magnetic field scan (output from first order pickup 
coil subtraction) as a function of scan distance..  
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Figure 10   Line Scan: Tumor at 10cm plus Virtual Organ Background  plus 
Diamagnetic Background 
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Figure 11:  Depth Dependence of Scanner  Signals. 
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